VANDERBILT UNIVERSITY SCHOOL OF MEDICINE BASIC SCIENCES

BOARD OF VISITORS

FALL 2019

Cover Image: Colony of human embryonic stem cells stained for the ac-tin cytoskeleton (magenta), myosin motors (cyan), and DNA (yellow).

Author: Nilay Taneja (Burnette lab).

— 1 —

Table of Contents

Agenda....................................................................3 Directions/Logistics..............................................4

Board Member Profiles........................................5

Basic Sciences Leadership Profiles....................13

Basic Sciences Department Chairs...................16

Development & Alumni Relations Staff...........25 Guidelines.............................................................27

— 2 —

— 3 —

Agenda

8:15 a.m. Dean’s Overview and Update U1202 MRB3

9:00 a.m. Discussion of Recruiting Talent by Board Members

9:45 a.m. Tour of Mass Spectrometry Research Center 9th Floor MRB3

10:15 a.m. Break MRB3 7th Floor Deck

10:40 a.m. Faculty Presentations U1202 MRB3 Matt Tyska Houra Merrikh Jeff Conn

12:00 p.m. William Pao Seminar & Lunch U1220 MRB3

1:15 p.m. Board-Student Networking U1202 MRB3

2:15 p.m. Positioning Vanderbilt for Transformative Gifts U1202 MRB3

3:15 p.m. Executive Session U1202 MRB3

— 4 —

Directions/LogisticsHotelThe block of rooms for BoV members is at the Kimpton Aertson, 2021 Broadway, at the intersections of 21st and Broadway, across from the Vanderbilt Law School. Parking for hotel guests is in their garage.

Dinner October 10Dinner will be held at Husk Nashville, 32 Rutledge Street, Nashville, TN 37210. Cocktailsbegin at 6:30 p.m., dinner at 7:00 p.m. Valet parking will not be available, however, there isparking accessible to the left and right of the building as well as a lot across the street.

Dinner LocationHusk Nashville (https://husknashville.com/dining). Located in Rutledge Hill—just a fewblocks south of Historic Broadway, in the heart of Downtown Nashville—Husk transformsthe essence of Southern food. Executive Chef Katie Coss reinterprets the bounty ofTennessee and the surrounding area, exploring an ingredient-driven cuisine that begins inthe rediscovery of heirloom products and redefines what it means to cook and eat in theSouth. Link to map: https://preview.tinyurl.com/HuskMap

Meeting Locations October 11 and Parking ArrangementsWe will convene for the morning session on the Vanderbilt campus in the Basic Sciencesconference room, U1202 MRB3, 465 21st Avenue South. Parking spots will be reserved forBoV members at the Wesley Place Garage, which is near the intersection of 21st and ScarrittPlace (2043 Scarritt Place is the address for your GPS). As you enter the garage, go to the 2ndlevel where spots are being held.

Medical Research Building (MRB) III

Ground TransportationFor anyone staying at the hotel, we will touch base with you as to whether you’d like to haveshuttle service from the hotel to: a) Husk Restaurant on Thursday night; b) the meetingroom on Friday morning; and c) the airport after the meeting on Friday.

— 5 —

Board Member ProfilesBrad Armstrong is a successful entrepreneur and businessman, currently based in Texas. He is a family member of the late Dr. Richard Armstrong, a Vanderbilt faculty member whose groundbreaking work formed a basis for understanding the enzymatic function of antibiotic resistance. Together with members of the Armstrong family, Brad was a leader in the creation of the Armstrong Family Fund and The Richard N. Armstrong, Ph.D. Chair for In-novation in Biochemistry.

Laurent Audoly, PhD, is a serial biotech entrepreneur and advises life sci-ences companies and investment funds on strategy, investment decisions, and business operations. Laurent has led business and R&D organizations in both pharma and biotech (US and EU), developing and operationalizing strategies, modernizing pipelines and business models, bringing forward drug candidates into and through development, and partnering on multiple projects (buy and sell). He has served as CEO, President, and board member of Kymera Thera-peutics where he led the construction of the business, raising over $130M and executing on > $1B in pharma partnership. Prior to this, Laurent was head of R&D with Pierre Fabre (multinational pharma with $2.5B in top line), where he led in/out-licensing of multiple clinical stage assets and technologies, re-built the organization, and directly contributed to IND entries, POC and LCM studies in oncology, dermatology, and neuropsychiatry. Earlier in his career, Laurent held positions of increasing leadership responsibilities on the business

and science sides at Pfizer, Merck, MedImmune, and Pieris contributing to the development of three approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology. Over the course of his career, Laurent has executed > $2B in pharma/biotech deals. He is also an inventor on several patents, has served on NIH study sections, and co-authored over 70 papers and patents. He studied chemistry (B.S. honors) and pharmacology (Ph.D.) at Vanderbilt University.

David L. Black, PhD, is currently a Clinical Associate Professor with an appointment in Pharmacology, Pathology, Microbiology and Immunolo-gy at Vanderbilt University. Dr. Black earned his undergraduate degree from Loyola College in Baltimore and doctorate degree in Forensic Toxicology from the University of Maryland at Baltimore (1982). Dr. Black is a Fellow of the American Board of Forensic Toxicology (F-ABFT) and a Fellow of the American Institute of Chemists (FAIC). Dr. Black was Department Head and Director of Toxicology for Maryland Medical Laboratory, Inc. from 1982-1986. He joined Vanderbilt University in 1986 as Assistant Professor with appointments in Pathology and Pharmacology. In 1990, Dr. Black founded Aegis Sciences Corporation where he served as Chairman and CEO until October of 2016. Aegis served as a forensic chemical and drug testing lab-oratory specializing in Zero-Tolerance Drug Testing® (proprietary process), employee drug testing (SAMHSA), professional and amateur athlete drug

testing (Doping Control), food/supplement analysis, pain management compliance testing, crime scene evi-dence analysis, driving under the influence of drugs and alcohol, and post-mortem evaluations. Dr. Black has served as Program Administrator for substance abuse programs for NASCAR, IndyCar and World Wrestling Entertainment (WWE) and as a consultant to Major League Baseball Players Association (MLBPA) and the National Football League Players Association (NFLPA). He has also served as a consultant to major corporations for development of substance abuse prevention policies and testing programs. He has testified extensively in local, state, national and international courts as an expert witness regarding drug use and test-ing programs. He is author/co-author of many peer reviewed published scientific papers in various scientific journals. Dr. Black is also Founder and President of Ebon-Falcon, LLC (a commercial real estate company),

— 6 —

and Founder and President of “2nd Vote” (a research organization monitoring Corporate social activism). Dr. Black served in the U.S. Marine Corps (1966-69) and in combat in Vietnam (1968-69) and is a 10% disabled veteran. Personal interests include church and community activities, Rotary International, Guatemala Med-ical/Dental/Vision Mission Trips. Dr. Black has been a Board member of the Nashville Healthcare Council and Life Sciences of Tennessee. Dr. Black lives in Gallatin, Tennessee, with his wife US Congressman Diane Black (TN 6th District), and they have three children and six grandchildren.

Andrea Carnegie, PhD, is the Chief Operating Officer of the North Carolina Translational and Clinical Sciences Institute. Prior to joining NC TRACS, she was the Director of Administrative Operations at the University of Illinois at the Chicago Center for Clinical and Translational Science. From 2007 to 2009, she was the administrative manager of the Oregon Retinal Degeneration Center at the Casey Eye Institute, Oregon Health & Science University in Portland, where she worked directly in clinical trial design and operations.

Dr. Carnegie received a BS in Biology at Emory and a PhD in Pharma-cology from Vanderbilt University as well as completing postdoctoral fel-lowships at Oregon Health & Science University. Her basic science work was on intracellular signaling mechanisms and biogenic amine transport in cardiac and neuronal cells. She is also an Assistant Professor of Medi-cine, in the Division of Endocrinology & Metabolism.

David Daniel, MD, is the Sr. VP and Chief Medical Officer of Brack-et Global. In this role, Dr. Daniel provides overall scientific, clinical and strategic direction for Bracket’s services. Prior to joining Bracket, Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He for-merly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation, and was a founding Principal of Best Practice, LLC. For over 20 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials in the United States and globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopatholo-gy of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders. Dr.

Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years. He is currently a Clinical Professor of Psychiatry and Behavior Sciences at George Washington University School of Medicine and Health Sciences.

— 7 —

Originally from West Lafayette, Indiana, Joann Data, MD, PhD, earned her MD at Washington University in St. Louis, before coming to Vanderbilt University to work on her PhD in Pharmacology with John Oates, MD, the Thomas F. Frist Sr. Professor of Medicine and the founding director of Vander-bilt University’s Division of Clinical Pharmacology. She earned her PhD in 1977, simultaneously completing her fellowship in Clinical Pharmacology and then serving as an instructor in Medicine and Pharmacology until her gradua-tion. Upon graduation, she joined The Upjohn Company doing cardiovascular clinical investigation. She held positions at Burroughs Wellcome and Compa-ny, and Hoffmann-La Roche prior to returning to The Upjohn Company where she became corporate vice president for Worldwide Pharmaceutical Regulatory Affairs and Project Management.

When Upjohn merged with Pharmacia, she joined CoCensys, Incorporated, as senior vice president of Clinical Development and Regulatory Affairs. From there she became the senior vice president of Regulatory Affairs and Quality Assurance at Amylin Pharmaceuticals, Incorporated. Over the course of her remarkable career, Dr. Data helped get 38 new drugs on the market, including two diabetes drugs (Symlin and Byetta), DepoProvera and Rogaine for Women. Today she is a consultant for the pharmaceutical industry and bioventure groups evaluating programs to see if their products are likely to make it to market and making recommendations regarding financial backing. Data serves on an advisory board working with Nancy Brown, MD, chair of the Department of Medicine, and former chief of the Division of Clinical Pharmacology.

Jon Duane is a Senior Partner Emeritus at McKinsey & Company and the Executive Chairman at Nashville Biosciences. Jon is a senior leader, advisor & hands-on consultant to top executives of large, complex private/public compa-nies, serving clients for 31 years in the pharma, medical-devices, life-sciences industries, and academic research. Known for his vision, impact, innovation & entrepreneurship, and for delivering huge wins to clients, Mr. Duane’s exper-tise includes advising top executive teams on corporate/BU strategy, business building, organizational design & performance improvement. He founded/led McKinsey’s Silicon Valley Office, created/led McKinsey’s Biotech practice & served as strategic thought leader on personalized medicine, emerging mar-kets, pricing of novel products & product life-cycle management.

Mr. Duane drove clients’ bottom-line impact/growth with work that had trans-formational results. He was a key player in enabling a stock price increase of 11%/year over ~10 years of service for a global, diversified healthcare prod-

ucts company by serving its CEO and top team across all BU and strategic topics, and paved the way for substan-tial shareholder value creation by facilitating the separation of the Pharma business to create 2 publicly-traded companies, subsequently contributing to a 20%/year share price increase for the new Pharma company. Mr. Duane unlocked a major academic center’s innovation by supporting key asset commercialization, leveraging IP & facilitating the spin out of a Genomics & Clinical Research Analytics business (~ $5M in revenue its first 2 years of operation), and the 2017 launch of an independent drug company.

He created shareholder value for a portfolio of cardiovascular medical device companies & enabled a biotech industry pioneer to pivot/become worldwide leader in Oncology. His many leadership roles at McKinsey include that of West Coast Healthcare Practice Leader; Chair, NA Client Service Risk Committee; and Master Faculty Member, McKinsey Partner U. He has an MBA from Harvard University and a BA from Wesleyan University.

— 8 —

Alexander “Zan” Fleming, MD, is President and CEO of Tolerion, a biotechnology company developing disease-modifying treatments for type 1 diabetes and other autoimmune diseases. He is also Founder and Exec-utive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices and digital health technologies. Dr. Fleming received his MD and internal medicine training from Emory University, fellowship training in endocrinology at Vanderbilt University and metabolism at National Insti-tutes of Health, where he was a senior fellow. At the US Food and Drug Ad-ministration (FDA) from 1986-98, Dr. Fleming was responsible for the ther-apeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, and reproductive indications. He led reviews of landmark approvals including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for

non-GH deficiency indications. Dr. Fleming oversaw clinical review of the earliest biotech products including human insulin and growth hormone. He helped to shape FDA policies and practices related to therapeutic review and regulatory communication. He was a major contributor to FDA’s Good Review Practice (GRP) initiative and led the committee responsible for education and training at CDER. He conceived and directed the first FDA pilot project to utilize the internet for regulatory communication. His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization, where he was assigned from FDA during 1991-92.

Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Consider-ations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group. Dr. Fleming is lead author of the book, Optimizing Development of Therapies for Diabetes. He has frequently published scientific articles and book chapters, the most recent chapter, “Regulatory Considerations for Early Clinical Development,” is in Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, published by Springer in October 2018. He has been a member of many corporate and advisory boards to academic and commercial institutions and professional societies. He serves on the joint technology working groups of the European Association for the Study of Diabetes and American Diabetes Association. Dr. Fleming coined the term, Metabesity, which refers to the constellation of cancer, heart and neurologic diseases, diabetes and the aging process itself, all which share common metabolic root causes and potential preventive therapies. He organized the first Congress on Metabesity in London in October 2017, which will be followed by the second Congress in Washington, D.C. in 2019.

Dennis Grimaud, CEO, RED Consulting, brings over 40 years of experi-ence in the health care industry and 30 years of experience in biotechnology as an entrepreneur, senior executive and consultant. He is currently Founder and CEO of Reliability, Execution, Development (RED), a healthcare and bio-technology company providing science, business and management services. He was most recently Chairman, CEO and Founder of DIATHERIX Laboratories, Incorporated, a clinical laboratory that provides testing services to physicians and hospitals for the identification of infectious disease through proprietary multiplexing PCR technology. He was CEO of Genaco Biomedical Products, Incorporated, providing Molecular Differential Diagnostics through multiplex-ing technology in infectious disease and cancer. He was also Chairman and CEO of Premier Micronutrient Corporation, a disease management company providing risk-based, disease specific micronutrient protocols that are adjunc-

tive to standard therapy. Dennis was Founder, Chairman and CEO of ScyTech, Incorporated, a company pro-viding management and business services to life science related biotechnology and health care companies. He also co-founded and was Chairman, President and CEO of Cytometry Associates, Incorporated, a specialized cancer testing facility providing clinical diagnostic testing services to physician specialists and biopharma-ceutical services to the pharmaceutical industry in drug discovery and clinical trials. Prior to Cytometry As-sociates he served as Vice President and General Manager of the Center for Clinical Sciences, a centralized

— 9 —

esoteric testing center for International Clinical Laboratories, Incorporated. He also held the positions of Vice President ICL East, responsible for turning around troubled operational divisions and Vice President of Sales and Marketing at ICL responsible for developing market strategy for cooperative agreements with hospitals. Prior to joining ICL he held two positions with National Medical Enterprises, Incorporated, as Administrator of Medical Diagnostics and Director of Laboratory Services in materials management providing consultation to over 150 hospitals and medical facilities nationwide.

Mr. Grimaud was a director of MedBioGene a publically traded biotechnology company in Vancouver, Can-ada. He served on the Board of Directors of Genaco Biomedical Products, Incorporated, and is a founding member and former director of the Nashville Health Care Council in Nashville, Tennessee. He was also a founding member Chairman and President of the Tennessee Biotechnology Association from 1998-2004. He is an invited speaker to healthcare payers, hospital corporations, boards of directors and academic institutions related to executive management programs. He is an advisor to Oliver Wyman, an international consulting firm.

Richard Hamilton, PhD, is the co-founder, President and CEO of Pros-per eDNA, a technology startup company focused on a consumer-based product that analyzes epigenetics to provide personalized recommendations on diet, exercise, mindfulness and aging. Before Prosper, Dr. Hamilton was the President and CEO of Ceres, Incorporated, a publicly held plant genomics company that was acquired by Land O’Lakes. Dr. Hamilton has more than 20 years of experience in biotechnology, genomics and finance. He served as Principal of Oxford Bioscience Partners, one of the leading investors in the genomics field. He has been active in the Biotechnology Industry Organiza-tion, where he has served as Vice Chairman of the organization, chaired its Food and Agriculture Governing Board and served in other leadership roles. He has been a member of the Keck Graduate Institute Advisory Council and was a Founding Member of the Council for Sustainable Biomass Production. He frequently speaks before policymakers, business leaders and scientific organizations regarding biotechnology and genomics. He has addressed the House Agriculture Committee, the President’s Council of Advisors on

Science and Technology and the National Academy of Sciences, among others. He has been a Director of Yield10 Bioscience, Incorporated, since March 2, 2017. From 1990 to 1991, he served as a Howard Hughes Medical Institute Research Fellow of Harvard Medical School.

Renee Bailey Iacona, PhD, MPH, is the VP and Head of Biomet-rics Oncology, R&D Oncology Unit, at AstraZeneca Pharmaceuticals. Re-nee joined AstraZeneca in 2001 and during her time here has experience of working across both early and late Oncology, as Global Product Statisti-cian, Line Manager, Alliance Director and Section Director for Stats & Pro-gramming (Wilmington and Sodertalje) before serving as Head of Alliance & Operations for Biometrics & Information Sciences. Since 2015, she has been the B&I TA Head for Oncology and Immuno-Oncology and an active member of the Oncology Development Review Committee, Oncology Ther-apy Area Leadership Team and Cancer Enterprise. Renee earned her PhD in

Pathology and MPH from Vanderbilt University. She currently co-chairs an external cross-Pharma initiative with the FDA looking into the effects of Non-Proportional Hazards on the design and interpretation of On-cology Trials.

— 10 —

Dr. William Pao, M.D. Ph.D., is the Head of Roche’s Pharmaceuti-cal Research & Early Development (pRED) unit, based in Basel, Switzer-land. In this position, he oversees the development of new molecules to treat a variety of diseases (neuroscience, ophthalmology, rare diseases, in-flammation, immunity, infectious diseases and oncology), spanning stages from target assessment to phase II clinical trials. Prior to his current posi-tion, he was the Global Head of the Oncology Discovery and Translation-al Area (DTA) for pRED. He obtained his MD and PhD degrees at Yale University, did his housestaff training in Internal Medicine at New York Presbyterian Hospital-Weill Cornell Campus, and completed his medical oncology and postdoctoral fellowship training at Memorial Sloan-Ketter-ing Cancer Center (MSKCC). He joined the faculty as MSKCC and was eventually recruited to Vanderbilt, where he became Professor of Medi-

cine, Director of the Division of Hematology/Oncology, and Director of Personalized Cancer Medicine at Vanderbilt-Ingram Cancer Center.

In his laboratory, he developed a basic and translational research program that made seminal contributions to the understanding of molecular mechanisms of solid tumor pathogenesis, with a particular focus on lung cancer. His work identified new molecular mechanisms of sensitivity and resistance of lung cancers to EGFR tyrosine kinase inhibitors (TKIs) and yielded important insights into a molecular understanding of lung ad-enocarcinoma in never smokers as well as thymic malignancies and melanoma. Based on these discoveries, he is co-patent holder on EGFR T790M mutation testing, and he developed and successfully tested new anti-cancer therapies in animal models and humans, including the combination of afatinib plus cetuximab as well as AZD9291 (osimertinib; Tagrisso) for patients with EGFR mutant tumors and resistance to EGFR TKIs. His work has helped change the standard of care in lung cancer.

Dr. Pao has received multiple honors and awards, including an ASCO Young Investigator Award, a Clinical Scientist Development Award from the Doris Durke Chariable Foundation, a V Foundation grant, the Hope Now Award from the Joan’s Legacy Foundation, and an SU2C Innovative Grant Award from the AACR.

Lee E Limbird, PhD, obtained her undergraduate degree in Chemis-try from the College of Wooster, Wooster, Ohio in 1970, and her PhD in Biochemistry from the University of North Carolina, Chapel Hill, in 1973. Her PhD research was in a directly clinically applicable area, the quantita-tion of the isoenzymes of CPK for identification of myocardial infarction in the context of confounding ECG findings. However, a postdoctoral fellowship with Robert J. Lefkowitz, MD, Duke University, transitioned her research focus to basic science research and to the molecular bases for epinephrine action through G protein-coupled receptors. Her own labora-tory at Vanderbilt University (1979-2014) focused on the affinity purifi-cation and identification of interacting partners for the alpha2-adrenergic receptor, and functional consequences in vitro and in vivo of mutation of the receptor to selectively disrupt coupling to one versus another signaling pathway. The laboratory also investigated the underlying molecular bases for receptor trafficking to distinct compartments in polarized cells. Her laboratory has been the recipient of many research awards. As Chair of Pharmacology at Vanderbilt University, Dr. Limbird enjoyed the privilege

of mentoring junior faculty in their career development; as the first Associate Vice Chancellor for Research at Vanderbilt Medical Center, Dr. Limbird fostered a focus on inter-disciplinary collaboration and discovery acceleration via establishment of critical Core Facilities for biomedical research. After retiring from Vander-bilt University in 2004, Dr. Limbird pursued in more depth her commitment to developing greater oppor-tunities for those currently under-represented in discovery and in scientific leadership via her roles first at Meharry Medical College (Vice President for Research and Chair of Biomedical Sciences) and now at Fisk University, as Professor and Dean of Graduate Studies.

— 11 —

Asit Parikh, M.D. Ph.D., earned his Ph.D in Biochemistry and MD degrees from Vanderbilt University, completed internal medicine residency at the University of Pennsylvania, and subspecialty training in gastroenterology at the Massachusetts General Hospital, with post-doctoral work in Cancer Biology at MIT. In 2006, Dr. Parikh joined the Clinical Research division at Millennium Pharmaceuticals where he focused on inflammation and early stage oncology clinical trials. There he led the development of vedolizumab (Entyvio), which represented the largest controlled clinical trial program ever conducted in inflammatory bowel disease. Since January 2012, Dr. Parikh has served as Therapeutic Area Head for General Medicines and Gastroenterology at Millennium’s parent company, Takeda Pharmaceuticals International, where he helps

guide Takeda’s global R&D strategy. Under his leadership, Takeda has achieved global approvals for En-tyvio, a Japan approval for Takecab for treatment of acid related disorders, in-licensed a molecule for IBD, and created a virtual GI drug discovery unit, all essential components of building a sustainable R&D pipeline focused on gastroenterology. Dr. Parikh maintains a commitment to research, patient care and teaching. He has authored a number of scientific manuscripts and presented at major scientific congresses. He continues to teach graduate students and residents as a guest lecturer, and is board certified and licensed to practice internal medicine and gastroenterology in the state of Massachusetts.

Dr. Colleen Elizabeth Piersen, PhD, currently holds the position of Assistant Head for Administration and Research Assistant Professor of Pharmacognosy in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Illinois at Chicago (UIC). She also serves in the role of Director of Research Services at the College level. Dr. Piersen has over twenty years of experience as a researcher, faculty member, or academic professional at four major research uni-versities and one biotechnology company. Her biomedical background is broad having conducted and/or managed basic through translational research in the fields of G-protein coupled receptors, DNA repair, repro-ductive health, and botanical dietary supplements. Much of her research

activity has focused on women’s health, especially during her tenure as Program Coordinator for the UIC/NIH Center for Botanical Dietary Supplements Research.

Colleen currently serves as the principal staff administrator in the Department of Pharmaceutical Sciences, and while she specializes in sponsored research administration, her responsibilities span research, finance, academic/faculty affairs, space, and human resources management. She has provided key administrative support for the establishment of two Board of Trustees-approved centers: the UIC/NIH Center for Botanical Dietary Supplements Research (1999 – present) and the UICentre for Drug Discovery (2012 – present). From 2015-2017, Dr. Piersen held the elected role of Chair of the UIC Academic Professional Advisory Committee (APAC). She concurrently served as Chair of the University [of Illinois] System Professional Personnel Ad-visory Committee (UPPAC) from 2015-2016. More recently, she was selected to participate in the 2018-2019 UI Academic Professional Leadership Program. Dr. Piersen holds a BA in Chemistry from Carleton College, a PhD in Pharmacology from Vanderbilt University, and an MBA in Healthcare Administration from Alaska Pacific University.

He was inducted into the Americana Society for Clinical Investigation in 2011 and the Association of the American Physicians in 2017. Dr. Pao also co-founded MyCancerGenome, an internationally-recognized online tool to enable a genetically-informed approach to cancer medicine. Throughout his career, Dr. Pao has served as a mentor for numerous junior faculty, postdoctoral fellows, medical fellows, medical students, PhD graduate students, college students, and high school students. Many of his lab mentees remain in aca-demia. He remains an Adjunct Professor of Medicine at Vanderbilt.

— 12 —

John-Kelly Warren is the CEO of the William K. Warren Founda-tion and is based in Tulsa, OK. The William K. Warren Foundation was created in 1945 by Mr. and Mrs. William Kelly Warren. The goal of the Foundation has been to provide the finest possible medical care avail-able to all patients utilizing Saint Francis Health System and to this end, it annually supports various medical programs. In addition to the hospi-tals and clinics, the Foundation created the William K. Warren Medical Research Center in 1973 that provides funds to medical investigators who participate in advanced medical research and creates environments that allow for the best possible delivery of care.

— 13 —

Basic Sciences LeadershipLawrence J. Marnett, Dean of Basic Sciences, is the Director of the A. B. Hancock, Jr. Memorial Laboratory for Cancer Research, Mary Geddes Stahlman Professor of Cancer Research, Professor of Biochemis-try, and Professor of Chemistry. Marnett received his Ph.D. in Chemistry from Duke University in 1973 and did postdoctoral work at the Karolins-ka Institute and Wayne State University. He began his academic career at Wayne State University where he rose through the ranks to Professor of Chemistry. Marnett’s research program focuses on the role of the enzyme cyclooxygenase-2 in cancer and inflammation as well as on the contribu-tion of normal metabolism to the generation of DNA damage and muta-tion. His group has used structure-based based approaches in conjunction with medicinal chemistry to design selective cyclooxygenase-2 inhibitors as potential anti-inflammatory, cancer preventive, and anti-angiogenic agents.

Marnett served as Associate Director of Basic Research of the Vanderbilt Ingram Cancer Center from 1993-2002, became Director of the Vander-

bilt Institute of Chemical Biology in 2002, and was named Associate Vice Chancellor for Research and Se-nior Associate Dean for Biomedical Sciences for the Vanderbilt University Medical Center in 2014. In 2016, he became the first Dean of Basic Sciences of the School of Medicine.

Roger Chalkley is the Senior Associate Dean for Biomedical Research Education and Training (BRET) and the professor of Molecular Physiology and Biophysics, School of Medicine at Vanderbilt. He is responsible for the overview of activities of the office of Biomedical Research Education and Training. These responsibilities include oversight of the PostDoctoral Affairs, the IGP, the MD/PhD Program, Ph.D. grant-ing programs as well as Minority Activities and supporting Training Grant applications. Dr. Chalkley was educated at Pembroke College, Oxford in Chemistry and conducted post-doctoral research in gene regulation and chromatin structure in the laboratory of James Bonner at CalTech. After almost 20 years in the Department of Biochemistry at the University of Iowa School of Medicine, he moved to Vanderbilt in 1986. He has pub-lished almost 200 papers in chromatin research. Dr. Chalkley has had an active interest in graduate education for many years and was involved in the establishment of the IGP where he served as Director for eight years.

— 14 —

Kathleen Gould is the Associate Dean for Biomedical Scienc-es, the Louise B. McGavock Chair, and Professor in the Department of Cell and Developmental Biology. Dr. Gould received her A.B. degree in Bio-chemistry from the University of California, Berkeley and her Ph.D. in Bi-ology from the University of California, San Diego. From 1988-90, she was a Fellow of the Jane Coffin Childs Memorial Fund for Medical Research at the University of Oxford with Sir Paul Nurse who was awarded a Nobel Prize in 2001. After joining the Vanderbilt faculty, Dr. Gould received the Boehringer-Ingelheim New Investigator Award, the Searle Scholar Award, and was an Investigator of the Howard Hughes Medical Institute from 1994-2013. Elected Fellow of the American Association for the Advancement of Science in 2011, Dr. Gould is also a member of several national professional societies and journal editorial boards, and serves regularly as reviewer for the National Institutes of Health and the Ford Foundation. At Vanderbilt, Dr. Gould has served in multiple leadership roles including Interim and Vice Chair of the Department of Cell and Developmental Biology, Director of the Vanderbilt International Scholar Program, and Chair of the institutional

biomedical/biological sciences internal review committee for limited submission opportunity applications. Dr. Gould is currently Director of Graduate Student Support and Associate Dean for Biomedical Sciences in the School of Medicine and leads Ph.D. trainee career development grants from the National Institutes of Health and Burroughs Wellcome Fund. Dr. Gould’s laboratory studies the mechanism and regulation of cell division, blending genetic, biochemical, genomic, structural, proteomic, and live cell imaging approaches to identify and characterize the constituents of the cytokinetic machinery and to discover how post-translational modifications of this machinery ensure the exquisite spatial and temporal control of cell division.

Alyssa Hasty, Associate Dean for Faculty Development, has been a member of the faculty in the Department of Molecular Physiology and Biophysics since 2003 and since 2014 she has been an investigator of the Tennessee Valley Veteran’s Administration Research Institute. She is an active member of the Vanderbilt Diabetes Center and the Digestive Diseases Research Center. Alyssa’s research interests are in diabetes and obesity, most recently focusing on the role of macrophages in promoting inflammation and insulin resistance in obesity. Alyssa has been very ac-tive in mentoring students as Director of Graduate Studies in MPB and faculty as Director of Career Development of the DDRC and Chair of the Women on Track Steering Committee. She is also Faculty Head of House of Murray House. Alyssa is currently participating in the Hedwingam van Ameringen Executive Leadership in Academic Medicine Program at Drex-el University.

— 15 —

Amy Major is an Associate Professor of Medicine, Division of Rheumatology and Immunology. She holds a secondary appointment in the Department of Pathology, Microbiology and Immunology. Amy con-ducted her graduate work in the laboratory of Dr. Christopher Cuff in the De-partment of Microbiology and Immunology, West Virginia University. There she studied the mucosal immune response of the small intestine against en-teric viruses. After earning her Ph.D. in 1998, Amy came to Vanderbilt as a postdoctoral fellow in the laboratories of Drs. MacRae Linton and Sergio Fazio where she studied immune-mediated mechanisms of atherosclerosis. She was appointed Assistant Professor in the Division of Cardiovascular Medicine, Vanderbilt University Medical Center in 2004. Amy was promot-ed to Associate Professor, with tenure, in 2014 and joined the Division of Rheumatology and Immunology in 2015. She is currently co-Director for T32 training grant and a K12 Career Development Grant. In addition, she is the Research Director for the Rheumatology and Immunology Clinical

Fellowship. In October of 2018 Amy extended her mentorship to undergraduate research by accepting the position of Faculty Director for Undergraduate Immersion in the School of Medicine.

Charles (Chuck) Sanders, Associate Dean for Research, has been on the faculty of the Biochemistry Department since 2002 and is an active member of the Center for Structural Biology. Chuck’s research in-terests focus on the role of membrane proteins, especially with flexible or unfolded structures, in the pathophysiology of cardiovascular and neurologic disorders. Chuck has won many awards for his research including the Hans Neurath Award of the Protein Society and the Stanley Cohen Award of Van-derbilt University School of Medicine. He has been a very active participant on research committees at Vanderbilt (e.g., Co-chair of TIPs Review Panel) and has served on multiple NIH study sections. He was Associate Editor of the journal, Biochemistry, from 2004-2015 and was interim Editor-in-Chief from 2015 to 2016.

Linda Sealy, Associate Dean for Diversity, Equity, and Inclu-sion, has been on the faculty of the Department of Molecular Physiology and Biophysics since 1986 and since 2006, has had a joint appointment in Cancer Biology. Her research focuses on the relationship between cell sig-naling and transcription in the control of cancer cell growth. Since 2007, Linda has served as Co-Director, then Director, of the Initiative for Maxi-mizing Student Diversity (IMSD), an NIH-sponsored grant for the graduate training of underrepresented minorities.

Under her leadership, the IMSD program has propelled Vanderbilt to the top echelon of institutions training minority Ph.D.’s. In fact, Vanderbilt was recently identified as the top producer of African-American Ph.D.’s in the US in biological and biomedical sciences. Her advocacy for holistic ad-mission in graduate recruiting has been recognized nationally as a critical advance in expanding the pipeline of graduate students to include underrep-

resented minorities. Linda has won numerous awards for her contributions to diversity in graduate education, including the Levi Watkins Jr. Faculty Award for Promoting Diversity and the inaugural Bishop Joseph A. Johnson Jr. Distinguished Leadership Professor Award.

— 16 —

Basic Sciences Department Chairs

Nancy Carrasco is the Joe C. Davis Chair in Biomedical Sci-ences, Professor and Chair of the Department of Molecular Physiology and Biophysics. Nancy Carrasco is a leading figure in the study of iodide transport and its critical role in the thyroid and mam-mary glands. She was the first to isolate the coding DNA for the iodide transporter protein (called NIS) that pulls iodide from the bloodstream into the thyroid gland. She received her M.D. and Masters in Biochemis-try degrees from the National Autonomous University of Mexico and did her postdoctoral training at the Roche Institute of Molecular Biology. She joined the Department of Molecular Pharmacology at the Albert Einstein College of Medicine as a faculty member in 1987 and the Department of Cellular and Molecular Physiology at the Yale School of Medicine in 2011. Dr. Carrasco joined the Vanderbilt faculty in the spring of 2019.

She is the recipient of the Pew Award in the Biomedical Sciences, the Ar-nold and Mabel Beckman Foundation Award, the Maria Sibylla Merian Award (Germany), the Merck Prize from the European Thyroid Association (Poland), the Marshall S. Horwitz Faculty Award (New York), and the Light of Life Award (New York), among others. She delivered the Rose Pitt-Rivers Lecture (Scotland) and the American Thyroid Association Plenary Lecture (Canada), and was named Coleman Fellow in the Life Sciences (Israel), among many other honors. Her research on the Na+/I- symporter (NIS), the key plasma membrane protein that mediates active iodide transport in the thyroid, lactating breast, and other tissues, rang-es from biochemical, biophysical, and physiological investigations to translational studies. She has served as president of the Society of Latin American Biophysicists. Dr. Carrasco was elected to the National Academy of Sciences in 2015.

Ege Kavalali is the William Stoke Chair in Experimental Therapeutics, Professor and Acting Chair of the Department of Pharmacology. Dr. Kavalali studies mechanisms of neurotransmis-sion and synaptic signaling in the central nervous system using electrical and optical recording techniques as well as molecular tools. As an under-graduate Dr. Kavalali studied Electrical Engineering at Bogazici University in Istanbul, Turkey. In 1995, he received his Ph.D. degree from Rutgers University, where he worked with Dr. Mark Plummer. In 1999, he complet-ed his postdoctoral studies with Dr. Richard W. Tsien at Stanford University in the Department of Molecular and Cellular Physiology. The same year, Dr. Kavalali joined the faculty at the Center for Basic Neuroscience at UT Southwestern led by Dr. Thomas C. Südhof. After 19 years of service at

UT Southwestern, in September 2018, Dr. Kavalali joined the Department of Pharmacology at Vanderbilt University as a Professor.

His group focuses on the molecular basis and functional consequences of heterogeneity among synaptic vesicle recycling pathways present within individual synapses. In particular, his work has uncovered the role and underlying mechanisms of spontaneous neurotransmitter release that holds it apart mechanistically and functionally from evoked neurotransmission. These studies gave rise to the hypothesis that spontaneous neurotransmission acts as an autonomous neuronal signaling pathway independent of action potential-evoked synaptic transmission. In addition, Dr. Kavalali and colleagues have identified spontaneous neurotransmis-sion-dependent signal transduction mechanisms that are required to trigger rapid antidepressant action.

— 17 —

Ian Macara is the Louise B. McGavock Professor and Chair-man of the Department of Cell and Developmental Biology at Vanderbilt University School of Medicine, currently the third highest ranked NIH funded cell biology department in the US. He also serves as co-chair of the Signal Transduction Program in the Vanderbilt Ingram Cancer Center. Previously, Dr. Macara was appointed the Harrison Distinguished Professor of Microbiology, was a Craig Scholar, directed the Advanced Microscopy Facility at the University of Virgina, and received the Distinguished Science Award before moving to Vanderbilt in 2012 to assume leadership of the De-partment of Cell and Developmental Biology.

Dr. Macara has studied various aspects of cancer biology for several de-cades, and has focused on cell polarity mechanisms for over 10 years with continuous funding from the NIH for over 30 years. A major goal of his laboratory is to tackle fundamental questions concerning the function of cell

polarity in mammary morphogenesis and breast cancer. He has published over 185 research papers, has an h-index of 82 (Google Scholar), and is placed in the top 5% of cited authors for journals in Biology and Bio-chemistry (per analysis by Thomson Reuters).

Dr. Macara is committed to the education of young scientists and has trained 35 graduate students and 35 postdoctoral fellows. Many have been highly productive with publications in top-ranked journals. At least 25%of the graduate students and about 50% of the postdocs have gone on to successful, independent academ-ic careers.

Dr. Macara is a member of the American Society of Cell Biologists (ASCB) and the American Society of Bi-ological Chemists. He is an elected fellow of the American Association for the Advancement of Science and currently serves on the Scientific Advisory Board of the Perlmutter Cancer Center at NYU. He has served on the ASCB Council and on the NCI Basic Research Board of Scientific Counselors. Dr. Macara received the Colin Thomson Memorial Medal by the Worldwide Cancer Research fund in recognition of his outstanding contribution to research into cancer by the Beatson International Conference. He organized and chaired the first EMBO conference on Cell Polarity and the first GRC conference on Cell Polarity, both of which have become annual conferences. Dr. Macara is currently on the editorial board as Senior Editor for Journal of Cell Biology, as Editor for Current Opinions in Cell Biology, and on the Editorial Board for Cellular Logistics.

John York is the Chair of Biochemistry and Natalie Over-all Warren Professor of Chemistry. His lab’s discovery-based and curiosity-driven science has garnered international attention in the field of cellular communication. York’s discoveries of pathways involved in signaling networks of organisms has led to new paradigms in the field and furthered our understanding of the pathophysiology of disease. Through these discoveries, he has co-founded and chaired several worldwide scien-tific meetings.

York is trained as a cellular and molecular biochemist and his research utilizes a multidisciplinary approach to study the underlying mechanisms of cellular signaling, including chemical codes such as inositides. Inositi-de signals are small ring-shaped molecules which have six arms that may be modified by addition of phosphate. York imagines that the complex pattern of chemical messengers produced by organisms allow for thou-sands of unique instructions, enabling regulation of cellular processes.

Basic-science discoveries from his laboratory have led to identification of disease genes and contributed to biomedical research.

— 18 —

In addition, York has contributed to institutional faculty governance and graduate education missions that have helped shape strategic and long-term support for the basic sciences. His professional duties include: Associate Editor of Molecular Biology of the Cell; member of the Burroughs Wellcome Fund’s Science Ad-visory Review Board; and past member of NIH grant review panels. York has trained over 40 scientists in his laboratory and has served on over 50 graduate student thesis committees. Under his leadership, Vanderbilt has revised graduate study expectations and focused on recruiting highly talented and diverse new faculty members.

York grew up outside of Chicago and received his BS in Biochemistry from the University of Iowa in 1986. After working at Merck Research labs, York started graduate school in 1990 in the laboratory of Dr. Philip Majerus and received his Ph.D. in Molecular and Cellular Biology and Biochemistry from Washington Uni-versity in 1993. York began his faculty career at Duke in 1996 as an Assistant Professor in Pharmacology and Biochemistry and rose through the ranks to Cancer Biology Distinguished Professor. In 2012, he moved to Vanderbilt to serve as Department Chair and Natalie Overall Warren Professor of Biochemistry. Among York’s awards are: Burroughs Wellcome Fund Career Award in the Biomedical Sciences, Whitehead Scholar, Howard Hughes Medical Institute Investigator, ASBMB Schering-Plough Science Achievement Award and election as a Fellow of the American Association for the Advancement of Sciences.

Richard M. Caprioli is the Director of the Mass Spectrometry Research Center and Stanford Moore Professor of Biochemistry and at Vanderbilt University School of Medicine. He is Principal Investigator of the National Institutes of Health Imaging Mass Spectrome-try National Resource. He is also currently Professor in the Departments of Chemistry, Medicine and Pharmacology at Vanderbilt University. Dr. Caprioli received his B.S. in 1965 from Columbia University in New York, N.Y., his Ph.D. in 1969 in Biochemistry, also at Columbia University with Professor Da-vid Rittenberg. After a one-year postdoctoral fellowship at Purdue University with Professor John H. Beynon, he was appointed as Assistant Professor of Biochemistry at Purdue in 1970. Dr. Caprioli moved to the University of Texas Medical School in Houston in 1975 where he was Professor of Biochemistry and Molecular Biology and Director of the Analytical Chemistry Center. He moved to Vanderbilt University in 1998 where he is currently Professor in the Departments of Biochemistry, Chemistry, Pharmacology and Internal Medicine.

Professor Caprioli’s general research interests lie in discovery of temporal and spatial processes in biological systems using mass spectrometry. This work has included technology developments in the areas of electrospray and laser desorption ionization mass spectrometry and their applications to intact tissues as well as other bio-logical samples. Applications have focused on achieving ultra-high sensitivity detection of endogenous com-pounds (e.g., neuropeptides) in intact tissues and in live animal systems. Recent work involves the development of Imaging Mass Spectrometry, a technology whereby molecular images of peptides, proteins, drugs and other compounds are localized in tissue sections with molecular weight specificity. Investigations to specific research areas involve elucidation of spatial distributions of molecules in both health and disease. Of special interest is the molecular distributions, spatial rearrangement, and alterations in expression levels of biological molecules in cancer tissues including human glioblastomas, breast cancer, colorectal cancer, prostate cancer and lung cancer.Dr. Caprioli has been a member of the American Society for Mass Spectrometry since 1975; he served two years each as President of the Society and Vice-President for Programs. He is a member of the American Society for Biochemistry and Molecular Biology, the American Association for Cancer Research, and the American Chem-ical Society. Professor Caprioli has been the Editor-in-Chief of the Journal of Mass Spectrometry since 1990. He is currently Series Editor of The Encyclopedia of Mass Spectrometry and additionally has edited several volumes in this encyclopedia. He has published over 300 scientific papers, including three books and holds 12 US patents involving mass spectrometry technologies. Dr. Caprioli recently served a 3-year term on the Board of Directors of HUPO and has been a member of the Board of Directors of the US HUPO since its inception.

— 19 —

Dr. Walter Chazin serves as Director of the Center for Struc-tural Biology and the Molecular Biophysics Training Pro-gram and holds the Chancellor’s Chair in Medicine as Professor in the Departments of Biochemistry and Chemistry. He received a B.Sc. in chem-istry from McGill University in 1975 and a Ph.D. in chemistry from Con-cordia University in Montreal in 1983. He was a postdoctoral fellow in the lab of Kurt Wüthrich at the E.T.H. in Switzerland (2002 Nobel laureate in Chemistry). After 13 years on faculty in the Department of Molecular Biology at the Scripps Research Institute, he moved to Vanderbilt in 1999. The Chazin laboratory uses an array of biophysical and structural tools to interrogate the structure, dynamics and function of proteins and pro-tein complexes involved in calcium signaling, the inflammatory re-sponse, innate immune response, and DNA replication, damage re-sponse and repair. With powerful structural information in hand, we can provide critical insights into the fundamental biology and medi-cine that drives our research. We use a “whatever it takes” attitude in terms of approaches that generates the many collaborations (tech-

nical, biological, medical) that is a hallmark of our research. While trained in protein NMR, we have evolved into having a broad-based vision of structural biology/molecular biophysics that involves the complementary application of structural approaches, including spectroscopy, scattering, crystal-lography and microscopy. This is also the philosophy that drives the Center for Structural Biology.

Dr. Chazin has mentored over 100 graduate students and postdocs in his 31 years as an independent inves-tigator. He has published more than 200 peer reviewed papers and ~50 book chapters and reviews, and serves on a number of advisory committees and editorial boards. His honors include American Cancer So-ciety Junior Faculty and Faculty Research Awards, serving as a National Academy of Science International Travel Fellow and as a NAS Teaching Fellow, Regents Visiting Professor at the University of Naples in Italy, the Vanderbilt Chancellor’s Award for Research and the Stanley Cohen Award, and appointments as Fellow of the American Association for the Advancement of Science and Fellow of the Biophysical Society.

In 2003, Dr. Caprioli received the Thomson Medal Award from the International Mass Spectrome-try Society for “for outstanding achievements in mass spectrometry and for distinguished service to in-ternational mass spectrometry.” He was named one of the “Pioneers in Proteomics” by the National Institutes of Health and received the Donald H. Coffey Award from the Society for Basic Urologic Re-search in 2005. He received the Field and Franklin Award from the American Chemical Society in April 2006 for Outstanding Achievement in Mass Spectrometry, the Eastern Analytical Society 2010 Award for Achievements in Mass Spectrometry and the HUPO Distinguished Achievement Award in Pro-teomic Sciences for 2010. Dr. Caprioli was elected a Fellow of the American Association for the Ad-vancement of Science (AAAS) in November 2012. Dr. Caprioli received the “Distinguished Contri-bution to Mass Spectrometry” Award by the American Society for Mass Spectrometry in June 2014.

— 20 —

Jeff Conn is the the Lee E. Limbird Professor of Pharma-cology at Vanderbilt University and Director of the Vander-bilt Center for Neuroscience Drug Discovery (VCNDD). Dr. Conn received a Ph.D. in Pharmacology from Vanderbilt in 1986 and pur-sued postdoctoral studies at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he where he established himself as a leader in studies of neurotransmitter re-ceptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn assumed the po-sition of Senior Director and Head of the Department of Neuroscience at Merck and Company in West Point, PA. In addition to directing the drug discovery efforts of his department in multiple CNS therapeutic areas, Dr. Conn was responsible for overseeing the global efforts of the com-

pany in discovery of new therapeutic agents for treatment of schizophrenia and movement disorders.

Dr. Conn moved to Vanderbilt University in 2003 where he is the founding director of the VCNDD, with a primary mission of facilitating translation of recent advances in basic science to novel therapeu-tics. By 2011 the VCNDD had grown to approximately 100 full time scientists and under his leader-ship raised over $100M in external research funding. In addition, the VCNDD advanced novel mol-ecules from multiple major programs into development for major brain disorders with industry partners, including Johnson and Johnson, Astrazeneca, Bristol Myers Squibb, and others. Each of these major ef-forts are focused on novel mechanisms for therapeutic action that have come from the basic research ef-forts of Dr. Conn and his collaborators. Dr. Conn has served as Associate Editor and Editor-in-Chief of Molecular Pharmacology and in editorial positions with multiple other international journals.

He has served the Scientific Advisory Boards of multiple foundations, research institutes, and compa-nies. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacol-ogy and Experimental Therapeutics (ASPET), Fellow of the American Association for the Advancement of Science, and on multiple national and international committees. He has received numerous awards, in-cluding the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Transla-tional Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Founda-tion Award for Excellence in Pharmacology and Toxicology. V. Sagar Sethi Mental Health Research Award, Jacob K. Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders & Stroke. He was named as an ISI Most- Cited Scientists in Pharmacology & Toxicology and the Lee Uni-versity 2008 Distinguished Alumnus of the Year. Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other serious brain disorders.

— 21 —

Lisa Monteggia is the Barlow Family Director of the Vander-bilt Brain Institute and Professor of Pharmacology at Vanderbilt University. Previously, Dr. Monteggia held the Ginny and John Eulich Pro-fessorship in Autism Spectrum Disorders and was Professor of Neuroscience at UT Southwestern Medical Center. Her lab focuses on the role of the mo-lecular and cellular basis of neural plasticity as it pertains to neuropsychiat-ric disorders. Her research interest has been focused in two areas. First, she is working to elucidate the mechanisms underlying antidepressant efficacy with implications towards depression, bipolar disorder, and suicide. Second, she is studying the role of Methyl-CpG-binding protein 2 (MeCP2), the gene linked to the autism spectrum disorder, Rett syndrome, on synaptic plastici-ty and behavior with implications towards a better understanding of neu-rodevelopmental disorders. Her research encompasses molecular, cellular, behavioral and electrophysiological approaches using preclinical models.

Dr. Monteggia was an undergraduate at the University of Illinois at Urbana-Champaign, receiving a B.S. in Microbiology and then a M.S. in Biology. Dr. Monteggia then worked for several years in a pharmaceutical company where she was promoted to the level of Sci-entist. Concurrently, Dr. Monteggia attended the Chicago Medical School receiving a Ph.D. in Neu-roscience and working with Dr. Marina Wolf in the area of drug abuse. Dr. Monteggia then moved to Yale University to complete a fellowship under the guidance of Dr. Eric Nestler in the area of molecu-lar psychiatry. During her postdoctoral research, Dr. Monteggia received a postdoctoral NRSA fel-lowship and a young investigator award from the National Alliance for Research on Schizophrenia and Depression (NARSAD). In 2002, Dr. Monteggia joined the Department of Psychiatry at UT South-western Medical School as an Assistant Professor. As an independent investigator, Dr. Monteggia has

Mark A. Magnuson is Director of the Center for Stem Cell Biology, Director of the Transgenic Mouse Shared Resource, and Lou-ise B. McGavock Chair and Professor of Molecular Physiology and Bio-physics, Cell and Developmental Biology, and Medicine. After obtaining a medical degree from the University of Iowa in 1979, Dr. Magnuson re-ceived clinical training in Internal Medicine at the University of Roches-ter, research training in Molecular Endocrinology at the NIH, and further training in both Clinical and Molecular Endocrinology at Vanderbilt pri-or to joining the faculty in 1987 with a primary appointment in Molecular Physiology and Biophysics. His research has long been focused on beta cell biology using reverse genetics in mice, and he has authored or co-authored over 230 scientific articles that have received over 29,000 citations. Be-tween 1998 and 2005, Dr. Magnuson served as Director of the Office of Biomedical Sciences and Assistant Vice Chancellor for Research. He is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians, a Fellow in the American Associ-

ation for the Advancement of Science, and the recipient of the Sidney P. Colowick Faculty Award. He has served on multiple scientific review panels for the NIH and other funding agencies, been a member of the NIDDK Advisory Council, and was chair of the Executive and Steering Committees of the NIDDK-fund-ed Beta Cell Biology Consortium for eleven years. In 2014 he received a Special Award from the NID-DK for his leadership of the Beta Cell Biology Consortium. His current research is focused on deciphering the gene regulatory network responsible for establishing pancreatic endocrine cell identity and determining how excitotoxicity and other metabolic stresses cause pancreatic beta cell failure. In addition, he is cur-rently using CRISPR mutagenesis in mice to explore the role of several zinc finger transcription factors in these gene networks and to understand how Sox17 gene expression is controlled during early development.

— 22 —

received numerous awards including the Daniel X. Freedman Award from NARSAD for out-standing research by a NARSAD young investigator, the Rising Star Award from the Internation-al Mental Health Research Organization, and the Daniel H. Efron Award for outstanding basic/trans-lational research by the American College of Neuropsychopharmacology. Dr. Monteggia has been recently elected as a Councilor for the Society for Neuroscience and current serves as a member of the National Institute of Health (NIH) Brain Initiative Working Group that reports to the NIH Director.

Dr. Monteggia is a Senior Editor of Neuropsychopharmacology and a member of the editori-al boards of eLife, Journal of Neuroscience, Journal of Biological Chemistry, Biological Psy-chiatry, and Hippocampus. She has served on grant review panels for the NIH as well as nu-merous scientific foundations and is a recognized leader in the field of molecular psychiatry and neuroscience. Dr. Monteggia is actively involved in advocacy and outreach initiatives and has a sustained history in training and mentoring students to successfully transition into academic and industry endeavors.

Gary A. Sulikowski, Director of the Institute of Chemical Bi-ology, received a BS in chemistry from Wayne State University and a PhD in organic chemistry from the University of Pennsylvania. He was an Amer-ican Cancer Society postdoctoral fellow at Yale University. His first facul-ty appointment was in the Department of Chemistry at Texas A&M Univer-sity in 1991 and joined the Vanderbilt Chemistry Department and Institute of Chemical Biology in 2004. He is the faculty Director of the Institute of Chemical Biology Chemical Synthesis core, Stevenson Professor of Chem-istry and Professor of Pharmacology. Sulikowski’s research interests are on the design and development of chemical syntheses of complex molecules, specifically bioactive natural products and molecular probes. Over time his interests have expanded to the chemical synthesis of molecular tools with application in biological research and therapeutic lead development. He has published over 125 research publications and co-authored 11 patents.

Dr. Sulikowski has received a number of fellowships and awards including an American Cancer Society Junior Faculty Fellowship, an Alfred P. Sloan Fellowship, an Association of Former Students of Texas A&M Teaching Award, an American Cyanamid Award and an Eli Lilly Research Award. He was named a Texas A & M Faculty Fellow from 2002-2007, American Association for the Advancement of Science Fellow 2008 and a Robert A. Welch Lecturer in 2004, and he was awarded a Japan Society for the Promotion of Science Fellowship in 2003.

Vito Quaranta, MD, is Director of the Quantitative Systems Bi-ology Center, Professor of Biochemistry at Vanderbilt University School of Medicine, Basic Science, and Director for the National Cancer Institute Center for Systems Biology of Small Cell Lung Cancer at Vanderbilt. For close to two decades he has been implementing cutting-edge interdisciplinary effort melding mathematics, engineering, computation and biology to solve the problems of cancer invasion, metastasis, and resistance to treatment. Dr. Quaranta has authored over 200 highly-cited scientific articles in the field of cancer and of systems biology, and several relevant chapters in medical books. He has trained close to 50 postdoctoral fellows, MSTP and PhD students.Dr. Quaranta has achieved international recognition for his contributions to can-cer systems biology. His accolades include election to Fellow of the American Association for the Advancement of Science; the Stanley Cohen Award for Out-

standing Contribution for Research Bridging Diverse Disciplines; the Apulians in the World Prize for Outstand-ing Achievements of Apulia Natives; NCI-sponsored Sigma Xi Distinguished Lecturer on Integrative Cancer Biology; Scholarship and Fellowship from Leukemia Society of America; Senior Fellowship from American Cancer Society, California Division; and Fellowship from Italian-American Medical Education Foundation.

— 23 —

Dr. Quaranta has been and is an invited lecturer at numerous congresses and conferences on can-cer systems biology. With Lourdes Estrada, Ph.D., he established an ongoing course in Cancer Sys-tems Biology at Vanderbilt University School of Medicine, and he lectures and holds workshops on the topic at national and international scientific meetings. He has also co-chaired the NCI’s Integrative Can-cer Biology Program. Dr. Quaranta is or has been in the Editorial Board of several scientific jour-nals, including Science Signaling, the Journal of Cellular Physiology and Cancer Research, routine-ly reviews for high-impact journals, and has been member of several NSF, NIH and NCI review panels.

The Quaranta laboratory applies both theory and experimentation to frame cancer as a complex adaptive sys-tem that responds to perturbations, such as drug treatment, by evolving over multiple biological and temporal scales. The laboratory is comprised of a mix of experimentalists, engineers, statisticians, and mathematicians combining experimental and modeling approaches iteratively towards a systems-level understanding of can-cer. A major focus of the laboratory is the development of single-cell methodologies to evaluate the mechanism of action of targeted therapy in cancer, based on the merging of automated time-lapse microscopy with image analysis and computational modeling. Another is the dynamics of transcription factor and signaling networks that define and maintain cell identity, and ultimately contribute to forming the phenotypic landscape of the tumor microenvironment. A recent achievement was the development of methods that measure drug-response dynamics of heterogeneous cancer cell populations as they emerge from single-cell behavior. These meth-ods are rapidly becoming a fundamental tool to understand the basis for cancer cell resistance to treatment.

Danny Winder is director of the Vanderbilt Center for Addiction Research, Associate Director of the Vanderbilt Med-ical Scientist Training Program, Professor of Molecular Physiology and Biophysics, Professor of Psychiatry and Behavioral Sciences, and Professor of Pharmacology. He received a BS in biology and chemistry from North Georgia College and a PhD in neuroscience from Emery University. Dr. Winder’s research focuses on synaptic mechanisms in addiction and anxiety. His lab has been particularly interested in 1) determining molecular mechanisms that modulate synaptic plasticity in the extended amygdala, 2) determining how and when these mechanisms are disrupted in alcoholism, and 3) de-termining the roles that modification of synaptic efficacy in these cir-cuits has on stress and reward-related behavior. Accomplishing these goals has required extensive use of whole cell patch clamp and ex-tracellular recordings in ex vivo brain slice preparations. He has had

a longstanding commitment to the use of mouse models to enable us to genetically perturb these circuits and to allow the use of genetically encoded reporters to mark specific neuronal populations for analysis.

Dr. Winder has a longstanding interest in training pre- and postdoctoral fellows in the use of electrophysio-logical approaches to study neuronal function. He has trained 13 successful PhD students to date, included 3 MD/PhD students. These former trainees are in postdocs and faculty positions across the country, including Dr. Zoe McElligott, on the faculty at UNC, Chapel Hill, Dr. Brad Grueter, on the faculty at Vanderbilt in the Department of Anesthesiology, and Dr. Bill Nobis, who is on the faculty of the Department of Neurol-ogy at Northwestern. Since 2008, five of his postdocs have earned K08 or K99 awards, all of whom have accepted tenure-track faculty positions at institutions across the country. Both Tom Kash and Sachin Patel won prestigious Presidential Early Career Awards for Scientists and Engineers (PECASEs) and now hold endowed chairs at their institutions. His postdoctoral mentorship was recently recognized at Vanderbilt with the F. Peter Guengerich Award for Mentoring Postdoctoral Fellows or Residents in the Research Setting.

— 24 —

Dr. Winder’s interests in graduate education are broad-based, as indicated by his service on the gradu-ate faculty council and executive council at Vanderbilt, by his roles with the interdisciplinary graduate pro-gram admissions committee and neuroscience graduate program, by his prior role as director of graduate studies for the Department of Molecular Physiology & Biophysics graduate training program, and by his current role as co-director of the neuroscience graduate program. He is also very interested in supporting and facilitating MD/PhD training, as evidenced by his role as Associate Director of the Vanderbilt MSTP.

— 25 —

Development & Alumni Relations Staff

Ellen Andrews, Development Coordinator, received her B.S. in Psychol-ogy from Wofford College in 2015. She began working in Development and Alumni Relations for Vanderbilt University in September 2018 on the Planned Giving team. In May 2018, she joined the School of Medicine, School of Nursing, and Basic Sciences team as the Development Coordina-tor. In this role, she focuses on stewarding donors of Vanderbilt University Basic Sciences and oversees The Discovery Circle, a society celebrating do-nors to the Basic Sciences.

Nicky Disbrow is the Associate Director of Leadership Annual Giving for the School of Medicine, School of Medicine - Basic Sciences, and School of Nursing at Vanderbilt. She is a graduate of Auburn University Montgomery, receiving her B.S. in Communication with a concentration in Public Relations. Nicky previously worked in Public Relations and Events at a small medical nonprofit in Auburn, Alabama before transitioning to de-velopment work in higher education. She served as the Development Man-ager, Direct Appeals at Oglethorpe University in Atlanta, Georgia and most recently worked as an Associate Director of Annual Giving at Emory Uni-versity in Atlanta, Georgia before moving into her current role at Vanderbilt.

Chris Cloar is the Associate Director of Leadership Annual Giving for the Basic Sciences at Vanderbilt. He is a graduate of Peabody College at Vanderbilt University, receiving his B.S. in Human and Organizational De-velopment and his M.Ed. in Higher Education Administration. Prior to this role, Chris served on the Stewardship team within Vanderbilt Development and Alumni Relations.

— 26 —

Aaron Conley is the Director of Corporate and Foundation Relations for the Basic Sciences at Vanderbilt. He is a graduate of Ohio University, receiving his B.S. in Creative Writing and World Religions. Prior to this role, Aaron served as the Director of Foundation Relations for the James Cancer Hospital at Ohio State University.

Taylor Wood, Associate Dean for Development, joined the Vanderbilt University Development and Alumni Relations team in November of 2018. His role focuses on raising support for the School of Medicine and the Basic Sciences with an emphasis on major gifts and strategic volunteer engagement. Prior to joining Vanderbilt, he was the Assistant Dean for Ad-vancement at the Syracuse University School of Architecture, serving as lead fundraiser for one of the top architecture programs in the country. Before assuming the aforementioned role in 2013, Taylor was the Director of Development for the College of Design at the University of Kentucky. He also served in positions early in his career in the development offices at Northern Kentucky University, Northern Illinois University and Ohio University. A Kentucky native, Taylor earned his Bachelor’s degree in English at the University of Kentucky and his Master’s degrees in Business Administration and Master’s in Sports Administration at Ohio University.

Zoe Weinman is the Development Assistant for the School of Medicine, Basic Sciences at Vanderbilt. She is a 2019 graduate of Vanderbilt Univer-sity, majoring in English and Political Science. While on campus she was involved with the Vanderbilt Equestrian Team and Phi Sigma Pi Honors Fraternity. Zoe is a native of Henderson, TN.

— 27 —

Basic Sciences Board of Visitors Guidelines

ARTICLE 1. Preamble

1.1 The name of this organization is the Vanderbilt University School of Medicine Basic Sciences Board of Visitors, hereinafter referred to as the Board.

1.2 The purpose of the Board is to support and foster the achievement of excellence in all aspects of research, teaching and career development for the students and faculty members of Vanderbilt University’s Basic Sciences departments, programs and centers. This shall be accomplished by proactive commitment to the following activities.

• Advising and supporting the Dean.• Assisting in developing beneficial relationships with industry, government, private foundations, and other academic institutions.• Reviewing and supporting strategic plans related to the Basic Sciences.• Reporting to the Chancellor and Provost on the status and opportunities related to the Basic Sciences.• Assisting in securing funds for important programs and opportunities in the Basic Sciences.• Making individual financial commitments to support the Basic Sciences.

ARTICLE 2. Membership

2.1 The Board membership is capped at 20 members. The members shall be alumni and non-alumni alike whose experience and accomplishments ensure the Board’s ability to achieve its purpose. Selection for membership shall be based on the candidate’s:

• demonstration of professional achievements in fields of importance to the Basic Sciences;• indication of a commitment to the University through service and financial support; and• enhancement of the balance of the Board’s breadth and diversity.

2.2 Appointments to the Board shall be made by the Dean. The Dean shall receive advice and nominations from the Chair of the Board the Executive Committee.

2.3 Members shall be appointed to the Board for a three-year term and may be appointed for a maximum of one additional consecutive terms of three years.

— 28 —

ARTICLE 3. Board Member Commitments

Board members are expected to be personally engaged in supporting the Basic Sciences at Vanderbilt in the following ways.

3.1 Attend all regular meetings and participate in Board activities and discussions by voicing opinions, displaying leadership and thinking strategically and creatively.

3.2 Make a personal financial investment in the Basic Sciences, to the best of one’s ability, making the School a personal philanthropic priority, thereby inspiring others. All Board member will be asked to become recurring members of its Discovery Circle, thereby providing generous annual support to empower the Dean to address the greatest needs and exciting opportunities.

3.3 Those members of the Board who become unable to meet these commitments or miss two consecutive meetings may be removed from the Board.

ARTICLE 4. Officers and Executive Committee

4.1 The Officers of the Board shall be comprise of the Chair, Vice-Chair, heads of the active Task Forces and the Dean. Together, they form the Executive Committee.

4.2 The Chair and Vice-Chair shall be appointed concurrently and shall both serve terms of two years. It is expected that, upon completion of the Chair’s term, the Vice-Chair shall be appointed to serve as Chair.

4.3 The Chair and Vice-Chair shall be appointed by the Dean upon consultation with the Executive Committee.

4.4 The Chair shall preside over the meetings of the Board and of the Executive Committee. The Vice-Chair shall preside in the absence of the Chair.

4.5 The Executive Committee advises the Dean of the School and Vice Provost of Research in matters such as Board membership, Task Force formation, selection of the Task Force chairs, and guidelines changes.

ARTICLE 5. Meetings

The Board shall meet in person twice a year, generally once in the fall and once in the spring. The Executive Committee may hold additional in-person or virtual meetings as needed. Notice of the meetings shall be sent at least three weeks prior to the meeting date.

— 29 —

ARTICLE 6. Task Forces

Task Forces shall be formed to address specific issues or reach specific objectives, and make recommen-dations to the Board. Each Task Force initially shall be active for one year, after which it can be renewed for additional years as needed by a vote of the members of the BOV.

ARTICLE 7. Adoption and Amendment

The bylaws shall be adopted and may be amended by a two-thirds majority of those in attendance at any regular meeting of the Board at which a quorum is present. A quorum is defined as forty percent or more of the membership of the Board.